NKTR 171
Alternative Names: NKTR-171Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Nektar Therapeutics
- Class Analgesics; Drug conjugates; Tricyclic antidepressants
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in USA (PO)
- 01 Jan 2014 Phase-I clinical trials in Neuropathic pain (in volunteers) in USA (PO)
- 15 Oct 2012 Pharmacodynamics data from a preclinical trial in Neuropathic pain presented at the 42nd Annual Meeting SfN - Neuroscience 2012 (SfN-2012) ,